Currently Viewing:
Supplements Importance of Selecting the Appropriate Therapy for Inflammatory Bowel Disease in the Managed Care E

Report: Economic Implications of Inflammatory Bowel Disease and Its Management

Foram Mehta, MS, RPh

Author affiliation: Aetna Medicare, Old Bridge, NJ.
Funding source: This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Author disclosure: Ms Mehta has no relevant financial relationships with commercial interests to disclose.
Authorship information: Acquisition of data; analysis and interpre-tation of data; and critical revision of the manuscript for important intellectual content.
Address correspondence to:

1. Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58(2):519-525. doi: 10.1007/s10620-012-2371-5.
2. The facts about inflammatory bowel diseases. Crohn’s & Colitis Foundation of America website. Published November 2014. Accessed September 15, 2015.
3. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis prac-tice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501-523. doi: 10.1038/ajg.2009.727.
4. Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104(2):465-483. doi: 10.1038/ajg.2008.168.
5. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel dis-eases. Gastroenterology. 2011;140(6):1785-1794. doi: 10.1053/j.gastro.2011.01.055.
6. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med. 2008;50(11):1261-1272. doi: 10.1097/JOM.0b013e318181b8ca.
7. Umanskiy K, Fichera A. Health related quality of life in inflam-matory bowel disease: the impact of surgical therapy. World J Gastroenterol. 2010;16(40):5024-5034.
8. Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis. 2005;11(10):909-918.
9. Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11(5):488-496.
10. Stone CD. The economic burden of inflammatory
bowel disease: clear problem, unclear solution. Dig Dis Sci. 2012;57(12):3042-3044. doi: 10.1007/s10620-012-2417-8.
11. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907-1913. doi: 10.1053/j.gastro.2008.09.012.
12. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol. 2003:98(5):1064-1072.
13. Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A. Health insurance paid costs and drivers of costs for patients with Crohn’s disease in the United States. Am J Gastroenterol. 2016;111(1):15-23. doi: 10.1038/ajg.2015.207.
14. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179-1187. doi: 10.1053/j.gastro.2012.08.002.
15. Everhart JE. Inflammatory bowel disease. In: Everhart JE, ed. The Burden of Digestive Diseases in the United States. Washington, DC: US Government Printing Office; 2008:97-106.
16. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology. 2009;136(3):741-754. doi: 10.1053/j.gastro.2009.01.015.
17. CDC/NCHS national hospital discharge survey: United States, 2010. CDC website. Accessed January 21, 2016.
18. Cohen R, Skup M, Ozbay AB, et al. Direct and indirect health-care resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. J Med Econ. 2015;18(6):447-456. doi: 10.3111/13696998.2015.1021353.
19. Meek PD, Racz MJ, Kehoe JE, Cosler LE, Carter JA, Yen L. Direct and indirect cost burden of ulcerative colitis: a matched analysis of healthcare costs, absenteeism, and short term disability costs in U.S. patients with and without ulcerative colitis. Gastroenterol. 2013;144(5 [suppl 1]):S-765.
20. Park MD, Bhattacharya J, Park K. Differences in healthcare expenditures for inflammatory bowel disease by insurance sta-tus, income, and clinical care setting. PeerJ. 2014;2:e587. doi: 10.7717/peerj.587.
21. Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17(7):1603-1609. doi: 10.1002/ibd.21488.
22. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24(2):319-328.
23. Bickston SJ, Waters HC, Dabbous O, Tang BI, Rahman M. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. J Manag Care Pharm. 2008;14(4):352-362.
24. Common practices in formulary management systems: a report prepared by the Academy of Managed Care Pharmacy. Academy of Managed Care Pharmacy website. http://www.amcp .org/WorkArea/DownloadAsset.aspx?id=9274. Published June 2000. Accessed January 14, 2015.
25. Porter ME. A strategy for health care reform--toward a value-based system. N Engl J Med. 2009;361(2):109-112. doi: 10.1056/NEJMp0904131.
26. Cohen JP, Stolk E, Niezen M. Role of budget impact in drug reimbursement decisions. J Health Polit Policy Law. 2008;33(2):225-247. doi: 10.1215/03616878-2007-054.
27. Physician Quality Reporting System. Centers for Medicare & Medicaid Services website. html?redirect=/pqri/. Updated December 23, 2015. Accessed January 21, 2016.
28. Melmed GY, Siegel CA. Quality improvement in inflammato-ry bowel disease. Gastroenterol Hepatol (N Y). 2013;9(5):286-292.
29. CCFA's Quality of Care Initiative. Crohn's & Colitis Foundation of America website. Accessed January 21, 2016.
30. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105(2):289-297. doi: 10.1038/ajg.2009.579.
31. Cohen RD, Waters HC, Tang B, Rahman MI. Effects of fistula on healthcare costs and utilization for patients with Crohn's dis-ease treated in a managed care environment. Inflamm Bowel Dis. 2008;14(12):1707-1714. doi: 10.1002/ibd.20530.
32. Hillson E, Dybicz S, Waters HC, et al. Health care expen-ditures in ulcerative colitis: the perspective of a self-insured employer. J Occup Environ Med. 2008;50(8):969-977. doi: 10.1097/JOM.0b013e31816fd663.
33. Mackowiak JI. A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of bal-salazide versus mesalamine in the treatment of ulcerative colitis. Manag Care Interface. 2006;19(10):39-46, 56.
34. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005;100(10):2239-2247.
35. Managing the costs of your IBD care. Crohn's & Colitis Foundation of America website. Accessed January 21, 2016.
36. Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther. 2006;13(6):502-506.
37. Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled mainte-nance treatment with infliximab for Crohn’s disease--modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008;28(1):76-87. doi: 10.1111/j.1365-2036.2008.03709.x.
38. Tsai HH, Punekar YS, Morris J, Fortun P. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2008;28(10):1230-1239. doi: 10.1111/j.1365-2036.2008.03839.x.
39. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose esca-lation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007;26(11-12):1509-1520.
40. Yu AP, Johnson S, Wang ST, et al. Cost utility of adalim-umab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease. Pharmacoeconomics. 2009;27(7):609-621. doi: 10.2165/11312710-000000000-00000.
41. Bakhshai J, Bleu-Lainé R, Jung M, et al. The cost effectiveness and budget impact of natalizumab for formulary inclusion. J Med Econ. 2010;13(1):63-69. doi: 10.3111/13696990903543424.
42. Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A. Health insurance paid costs and drivers of costs for patients with Crohn’s disease in the United States. Am J Gastroenterol. 2016;111(1):15-23. doi: 10.1038/ajg.2015.207.
43. Van der Valk M, Mangen MJ, van der Have M, et al. P525 evo-lution of IBD-related costs over two years of follow up: increase of anti-TNF ± therapy related costs with a decline of hospitalization costs. European Crohn’s and Colitis Organisation website. Published 2015. Accessed January 28, 2016.
44. Rubin DT, Mody R, Davis KL, Wang CC. Real-world assess-ment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn’s disease. Aliment Pharmacol Ther. 2014;39(10):1143-1155. doi: 10.1111/apt.12727.
45. Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39(12):1349-1362. doi: 10.1111/apt.12749.
46. Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19(7):1528-1533. doi: 10.1097/MIB.0b013e31828132cb.
47. Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009;29(3):247-257. doi: 10.1111/j.1365-2036.2008.03865.x.
48. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53(4):1020-1024.
49. Sandborn WJ, Hanauer S, Van Assche G, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014;8(9):927-935. doi: 10.1016/j.crohns.2014.02.021.
50. Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7(1):6-19. doi: 10.1038/mi.2013.73.
51. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106(4):674-684. doi: 10.1038/ajg.2011.60.
52. Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF. Loss of treat-ment response to infliximab maintenance therapy in Crohn’s disease: a payor perspective. Value Health. 2008;11(5):820-829. doi: 10.1111/j.1524-4733.2008.00335.x.

Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up